
Verrica Pharmaceuticals Posts Strong Q2 Growth, Advances Basal Cell Carcinoma Program
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported second-quarter 2025 revenue of $12.7 million, driven by continued commercial momentum for its lead product, YCANTH®, and milestone payments from …
Verrica Pharmaceuticals Posts Strong Q2 Growth, Advances Basal Cell Carcinoma Program Read More